ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DMGT Daily Mail & General Trust Plc

270.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Daily Mail & General Trust Plc LSE:DMGT London Ordinary Share GB00BJQZC279 'A'ORD(NON.V)12.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 270.00 270.00 271.50 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Daily Mail & General Trust PLC Closure of Xceligent (4367Z)

15/12/2017 7:00am

UK Regulatory


Daily Mail & General (LSE:DMGT)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Daily Mail & General Charts.

TIDMDMGT

RNS Number : 4367Z

Daily Mail & General Trust PLC

15 December 2017

15 December 2017

Daily Mail and General Trust plc (DMGT)

Closure of Xceligent

On 30 November 2017, DMGT announced that the new management team at Xceligent, the US Property Information business, was undertaking a strategic review. This followed a reduction in the carrying value of Xceligent to zero.

DMGT has now announced that, following completion of the strategic review, the Board of Xceligent, Inc. has decided to file for Chapter 7 liquidation.

Under US law, a Chapter 7 trustee with expertise in liquidating companies will be appointed to distribute Xceligent's assets under well-established statutory law and a federal judge with financial expertise will oversee the proceedings in a public forum.

Full responsibility for all current litigation involving Xceligent will be assumed by the Chapter 7 trustee. DMGT holds no liability for any future costs associated with the litigation.

The guidance for FY 2018, given on 30 November 2017, remains unchanged. The adjusted operating margin of DMGT's B2B portfolio of businesses is still expected to be in the mid-teens, including Xceligent's closure costs. DMGT does not expect to incur any further exceptional cash costs relating to Xceligent.

The information communicated in this announcement includes inside information.

For further information

 
 For analyst and institutional 
  enquiries: 
 Tim Collier, Chief Financial 
  Officer                            +44 20 3615 2902 
 Adam Webster, Head of Management 
  Information 
   and Investor Relations            +44 20 3615 2903 
 
 For media enquiries: 
  Paul Durman / Doug Campbell, 
  Teneo Blue Rubicon                   +44 20 7260 2700 
 

About DMGT

DMGT manages a diverse, multinational portfolio of companies, with total revenues of around GBP1.5 bn, that provide businesses and consumers with compelling information, analysis, insight, events, news and entertainment. DMGT is also a founding investor and the largest shareholder of Euromoney Institutional Investor PLC and ZPG Plc.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCTIBTTMBTBTBR

(END) Dow Jones Newswires

December 15, 2017 02:00 ET (07:00 GMT)

1 Year Daily Mail & General Chart

1 Year Daily Mail & General Chart

1 Month Daily Mail & General Chart

1 Month Daily Mail & General Chart

Your Recent History

Delayed Upgrade Clock